Cleopatra Study HER2 Positive Metastatic Breast Cancer

  • The CLEOPATRA study:
    • Showed that the combination of docetaxel, trastuzumab, and pertuzumab:
      • Led to improved progression free survival (PFS) compared to docetaxel, trastuzumab, and placebo:
        • 18.5 months vs. 12.4 months
    • Surgery for the primary site:
      • Is not indicated for patients with distant metastatic disease in the absence of symptoms
  • References
    • Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. New Engl J Med.2012;366(2):109-119.
    • Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724-734.

Leave a comment